At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 97 enrolled
Drug / intervention
Donepezil HCldrug
Likely dose
Donepezil HCl 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Week, Multicenter, Open Label Study To Evaluate The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility
In Brief
A Phase 4 clinical trial evaluating Donepezil HCl for Mild to Severe Alzheimer's Disease. Completed, enrolled 97 participants across 36 sites.
Detailed Summary
This is a study to determine the effectiveness and safety of donepezil hydrochloride (E2020) used to treat residents of assisted living facilities diagnosed with mild, moderate, or severe stage Alzheimer's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild to Severe Alzheimer's Disease
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2007
Enrollment StartJan 2008
Primary CompletionDec 2008
Study CompletionApr 2009
TodayJul 2026
First PostedDec 11, 2007
Enrollment StartJan 1, 2008
Primary CompletionDec 1, 2008
Study CompletionApr 22, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.6 years ago
Interventions
Donepezil HCldrug
One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.